-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Human -X- _ O
parainfluenza -X- _ O
virus -X- _ O
type -X- _ O
3 -X- _ O
( -X- _ O
HPIV3 -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
common -X- _ O
cause -X- _ O
of -X- _ O
upper -X- _ O
and -X- _ O
lower -X- _ O
respiratory -X- _ O
tract -X- _ O
illness -X- _ O
in -X- _ O
infants -X- _ O
and -X- _ O
young -X- _ O
children. -X- _ O
Live-attenuated -X- _ B-Intervention
cold-adapted -X- _ I-Intervention
HPIV3 -X- _ I-Intervention
vaccines -X- _ I-Intervention
have -X- _ O
been -X- _ O
evaluated -X- _ O
in -X- _ O
infants -X- _ O
but -X- _ O
a -X- _ O
suitable -X- _ O
interval -X- _ O
for -X- _ O
administration -X- _ O
of -X- _ O
a -X- _ O
second -X- _ O
dose -X- _ O
of -X- _ O
vaccine -X- _ O
has -X- _ O
not -X- _ O
been -X- _ O
defined. -X- _ O
METHODS -X- _ O
: -X- _ O
HPIV3-seronegative -X- _ B-Patient
children -X- _ I-Patient
between -X- _ I-Patient
the -X- _ I-Patient
ages -X- _ I-Patient
of -X- _ I-Patient
6 -X- _ I-Patient
and -X- _ I-Patient
36 -X- _ I-Patient
months -X- _ I-Patient
were -X- _ O
randomized -X- _ O
2:1 -X- _ O
in -X- _ O
a -X- _ O
blinded -X- _ O
study -X- _ O
to -X- _ O
receive -X- _ O
two -X- _ B-Intervention
doses -X- _ I-Intervention
of -X- _ I-Intervention
10 -X- _ I-Intervention
( -X- _ I-Intervention
5 -X- _ I-Intervention
) -X- _ I-Intervention
TCID -X- _ I-Intervention
( -X- _ I-Intervention
50 -X- _ I-Intervention
) -X- _ I-Intervention
( -X- _ I-Intervention
50 -X- _ I-Intervention
% -X- _ I-Intervention
tissue -X- _ I-Intervention
culture -X- _ I-Intervention
infectious -X- _ I-Intervention
dose -X- _ I-Intervention
) -X- _ I-Intervention
of -X- _ I-Intervention
live-attenuated -X- _ I-Intervention
, -X- _ I-Intervention
recombinant -X- _ I-Intervention
cold-passaged -X- _ I-Intervention
human -X- _ I-Intervention
PIV3 -X- _ I-Intervention
vaccine -X- _ I-Intervention
( -X- _ I-Intervention
rHPIV3cp45 -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ O
placebo -X- _ B-Comparison
6 -X- _ O
months -X- _ O
apart. -X- _ O
Serum -X- _ O
antibody -X- _ O
levels -X- _ O
were -X- _ O
assessed -X- _ O
prior -X- _ O
to -X- _ O
and -X- _ O
approximately -X- _ O
4-6 -X- _ O
weeks -X- _ O
after -X- _ O
each -X- _ O
dose. -X- _ O
Vaccine -X- _ O
virus -X- _ O
infectivity -X- _ O
, -X- _ O
defined -X- _ O
as -X- _ O
detection -X- _ O
of -X- _ O
vaccine-HPIV3 -X- _ O
in -X- _ O
nasal -X- _ O
wash -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
a -X- _ O
â‰¥ -X- _ O
4-fold -X- _ O
rise -X- _ O
in -X- _ O
serum -X- _ O
antibody -X- _ O
titer -X- _ O
, -X- _ O
and -X- _ O
reactogenicity -X- _ O
were -X- _ O
assessed -X- _ O
on -X- _ O
days -X- _ O
3 -X- _ O
, -X- _ O
7 -X- _ O
, -X- _ O
and -X- _ O
14 -X- _ O
following -X- _ O
immunization. -X- _ O
RESULTS -X- _ O
: -X- _ O
Forty -X- _ B-Outcome
HPIV3-seronegative -X- _ I-Outcome
children -X- _ I-Outcome
( -X- _ I-Outcome
median -X- _ I-Outcome
age -X- _ I-Outcome
13 -X- _ I-Outcome
months -X- _ I-Outcome
; -X- _ I-Outcome
range -X- _ I-Outcome
6-35 -X- _ I-Outcome
months -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
enrolled -X- _ I-Outcome
; -X- _ I-Outcome
27 -X- _ I-Outcome
( -X- _ I-Outcome
68 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
received -X- _ I-Outcome
vaccine -X- _ I-Outcome
and -X- _ I-Outcome
13 -X- _ I-Outcome
( -X- _ I-Outcome
32 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
received -X- _ I-Outcome
placebo. -X- _ I-Outcome
Infectivity -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
25 -X- _ I-Outcome
( -X- _ I-Outcome
96 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
26 -X- _ I-Outcome
evaluable -X- _ I-Outcome
vaccinees -X- _ I-Outcome
following -X- _ I-Outcome
dose -X- _ I-Outcome
1 -X- _ I-Outcome
and -X- _ I-Outcome
9 -X- _ I-Outcome
of -X- _ I-Outcome
26 -X- _ I-Outcome
subject -X- _ I-Outcome
( -X- _ I-Outcome
35 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
following -X- _ I-Outcome
dose -X- _ I-Outcome
2. -X- _ I-Outcome
Among -X- _ I-Outcome
those -X- _ I-Outcome
who -X- _ I-Outcome
shed -X- _ I-Outcome
virus -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
median -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
shedding -X- _ I-Outcome
was -X- _ I-Outcome
12 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
range -X- _ I-Outcome
, -X- _ I-Outcome
6-15 -X- _ I-Outcome
days -X- _ I-Outcome
) -X- _ I-Outcome
after -X- _ I-Outcome
dose -X- _ I-Outcome
1 -X- _ I-Outcome
and -X- _ I-Outcome
6 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
range -X- _ I-Outcome
3-8 -X- _ I-Outcome
days -X- _ I-Outcome
) -X- _ I-Outcome
after -X- _ I-Outcome
dose -X- _ I-Outcome
2 -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
mean -X- _ I-Outcome
peak -X- _ I-Outcome
log -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
) -X- _ I-Outcome
viral -X- _ I-Outcome
titer -X- _ I-Outcome
of -X- _ I-Outcome
3.4 -X- _ I-Outcome
PFU -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
( -X- _ I-Outcome
SD -X- _ I-Outcome
: -X- _ I-Outcome
1.0 -X- _ I-Outcome
) -X- _ I-Outcome
after -X- _ I-Outcome
dose -X- _ I-Outcome
1 -X- _ I-Outcome
compared -X- _ I-Outcome
to1.5 -X- _ I-Outcome
PFU -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
( -X- _ I-Outcome
SD -X- _ I-Outcome
: -X- _ I-Outcome
0.92 -X- _ I-Outcome
) -X- _ I-Outcome
after -X- _ I-Outcome
dose -X- _ I-Outcome
2. -X- _ I-Outcome
Overall -X- _ I-Outcome
, -X- _ I-Outcome
reactogenicity -X- _ I-Outcome
was -X- _ I-Outcome
mild -X- _ I-Outcome
, -X- _ I-Outcome
with -X- _ I-Outcome
no -X- _ I-Outcome
difference -X- _ I-Outcome
in -X- _ I-Outcome
rates -X- _ I-Outcome
of -X- _ I-Outcome
fever -X- _ I-Outcome
and -X- _ I-Outcome
upper -X- _ I-Outcome
respiratory -X- _ I-Outcome
infection -X- _ I-Outcome
symptoms -X- _ I-Outcome
between -X- _ I-Outcome
vaccine -X- _ I-Outcome
and -X- _ I-Outcome
placebo -X- _ I-Outcome
groups. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
rHPIV3cp45 -X- _ B-Outcome
was -X- _ I-Outcome
immunogenic -X- _ I-Outcome
and -X- _ I-Outcome
well-tolerated -X- _ I-Outcome
in -X- _ I-Outcome
seronegative -X- _ I-Outcome
young -X- _ I-Outcome
children. -X- _ I-Outcome
A -X- _ I-Outcome
second -X- _ I-Outcome
dose -X- _ I-Outcome
administered -X- _ I-Outcome
6 -X- _ I-Outcome
months -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
initial -X- _ I-Outcome
dose -X- _ I-Outcome
was -X- _ I-Outcome
restricted -X- _ I-Outcome
in -X- _ I-Outcome
those -X- _ I-Outcome
previously -X- _ I-Outcome
infected -X- _ I-Outcome
with -X- _ I-Outcome
vaccine -X- _ I-Outcome
virus -X- _ I-Outcome
; -X- _ I-Outcome
however -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
second -X- _ I-Outcome
dose -X- _ I-Outcome
boosted -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
and -X- _ I-Outcome
induced -X- _ I-Outcome
antibody -X- _ I-Outcome
responses -X- _ I-Outcome
in -X- _ I-Outcome
two -X- _ I-Outcome
previously -X- _ I-Outcome
uninfected -X- _ I-Outcome
children -X- _ I-Outcome
. -X- _ O

